Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veligrotug in Thyroid Eye Disease
NCT05176639Phase 3Completed
- Sponsor
- Viridian Therapeutics
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in thyroid eye disease (TED) comparing Veligrotug with Placebo (2 arms). Primary endpoint: Proptosis Responder Rate at 15 weeks. Started Nov 2022; status: completed.
02
Drugs
veligrotug
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05176639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176639.